Lonza Plans to Double Turnover in India by 2024, Expand Market

Lonza India, a wholly-owned subsidiary of the Basel (Switzerland)-headquartered 5.5 billion CHF (Swiss Franc)  world's leading, integrated solutions provider for pharma and consumer healthcare, announced its India plan. India being a strategic market for the company, Lonza India with turnover for around 100 million CHF (Swiss Franc) has set the target of doubling its turnover by 2024 with an estimated growth of 15 + percent.

Lonza India, which offers product portfolio in India and covers an entire life sciences industry has taken up an aggressive expansion plan by announcing corporate offices across the country in the current financial year. The company aims to facilitate bilateral businesses and scientific partnerships with Switzerland, has built a wide network of representations across India.

Lonza set out on its Indian journey in 1997, setting up a liaison office. The office was involved mainly into sourcing advanced intermediates from India. Subsequently, Lonza acquired Cambrex Bio Products in 2007 and started as a full-fledged sales and commercial organization and then it was renamed as Lonza India Pvt. Ltd. in 2008.

Deepak Sood, Managing Director, Lonza India Pvt. Ltd, said that their activities also include the sourcing of intermediates from strategic partners for their manufacturing plants worldwide. In India, they are catering to the Pharma sector giants such as Cipla, Sun, Aurobindo, DRL, Himalaya, Patanjali, and Dabur. Our customers in FMCG include HUL, Asian Paints, Berger, and P&G.  Life sciences are yet another core area for Lonza and they are catering to research institutes like IIT, JNU, NII, ICGEB and medical device companies like Baxter, Brawn. They are also expanding their markets in Nutraceuticals and Petrochemicals segments, he said.

He pointed out that the offerings from the company’s stable consist of various products for cell discovery, molecular biology, rapid testing tools, fine chemical intermediates and pharma and intermediates for agrochemicals, consumer health & nutrition. Besides, it also has biocides for industrial application, disinfectants for hospitals and various performance chemicals. Sood is spearheading Lonza’s India operations with over 29 years of industry experience in India & Asia Pacific in the field of Health care space.

Lonza India is now focusing on achieving the strategic vision of being a leading, integrated solutions provider for its pharma and consumer healthcare and nutrition customers all along the healthcare continuum in India.

As part of the company’s commitment to the welfare of the people of India and its own deep-rooted values, Lonza India also announced its partnership with two NGOs Suraksha Foundation and StratSol Foundation to carry out its CSR work. Lonza intends to carry forward its legacy of inclusive growth for the society around its plant in continuation to the same Lonza will undertake CSR initiatives towards water conservation in the area around the plant it will also undertake projects related to lighting the area thru renewable energy source, added Andreas Bohrer, Group General Counsel, Lonza AG.

The company leverages global supply chains for its business growth, but Lonza also has the flexibility to address regional and even local marketplace needs. The Swiss company also adopts a sustainable approach to minimize its impact on the environment, conserving energy and natural resources, and to help improve the quality of life.